Investment Plan for Europe: European Investment Bank to provide BioNTech with up to €100 million in debt financing for COVID-19 vaccine development and manufacturing

vaccinations_

(Credit: Unsplash)

This article is brought to you in association with the European Commission.


  • EIB debt instrument will support BioNTech’s global development of BNT162 for prevention of COVID-19 infection as well as scale-up of manufacturing capacity in Europe as part of the company’s global development and supply strategy
  • The project benefits from Horizon 2020 InnovFin and the European Fund for Strategic Investments, joint instruments of the European Commission and the EIB

The European Investment Bank (EIB) and BioNTech (Nasdaq: BNTX, BioNTech) today concluded a €100 million debt financing agreement to support the development of BNT162, the company’s COVID-19 vaccine programme. The deal will also allow the company to expand its manufacturing capacity in order to supply the vaccine fast worldwide in response to the pandemic. This will be done at the company’s own risk while the clinical studies are ongoing. BioNTech became the first European company to enter clinical testing, having started a clinical trial in Germany in April and a further clinical trial in the United States at the beginning of May. BioNTech’s development programme for BNT162 is one of the broadest development programmes globally, with four vaccine candidates being tested in parallel.

mRNA vaccines consist of genetic material, called messenger RNA, that provides instructions for a human cell to make a target protein, or immunogen, which activates the body’s immune response against the respective virus. The goal of a vaccine is to stimulate the immune system to generate protective, long-lasting antibody and T cell responses against SARS-CoV-2 and prevent subsequent infection upon exposure to the virus. mRNA vaccines are a potent new developmental class of vaccines with potential for high versatility and favourable safety properties. BioNTech was able to bring the first vaccine candidates from concept into clinical testing in less than three months. Safety, speed and flexibility are of the utmost importance in reacting to the current pandemic.

The EIB debt investment will be disbursed in two tranches of €50 million each, following completion of pre-defined milestones. It is backed by the European Fund for Strategic Investments, the financial heart of the Investment Plan for Europe, in which the EIB and the European Commission partner to kick-off investment for EU priority projects. It also benefits from InnovFin Risk Sharing for Corporate Research backed by Horizon 2020, the EU Framework Programme for Research and Innovation.

Mariya Gabriel, Commissioner for Innovation, Research, Culture, Education and Youth, said: “As part of our efforts to counter the spread of the coronavirus, we have embarked decisively on the worldwide race to find an effective and safe vaccine as quickly as possible. For this purpose we recently launched the Coronavirus Global Response initiative, while at the same time we mobilised significant funding through Horizon 2020 for research projects aimed at developing a prophylactic and a therapeutic vaccine. I am very pleased that today, together with the European Investment Bank, we are extending our support to BioNTech, which is yet another concrete step towards our goal of getting a vaccine and ensuring access to it for all.

The only way to end the dramatic situation the world has been facing since the outbreak of the coronavirus pandemic is to come up with a safe and effective vaccine,” said Ambroise Fayolle, EIB Vice-President in charge of innovation. “In recent years the EIB has become a unique player in supporting highly innovative venture-stage biotech and medtech companies in their research and development of vaccines, therapeutics and diagnostics solutions, and we are doing everything we can to step up our support in the current crisis.”

The investments we have made to develop our vaccine platform over the past 12 years have been instrumental in enabling us to develop our COVID-19 vaccine programme rapidly in response to the global health crisis,” said Sierk Poetting, Chief Financial Officer & Chief Operating Officer of BioNTech. “This funding commitment by the EIB will further support the next stage of our COVID-19 scale-up activities as we expand our production capacity to enable global supply.

BioNTech already entered into a €50 million venture debt agreement under the European Growth Finance Facility for its personalised cancer immunotherapy programme in December 2019. The financing was part of broader EIB activities in the life sciences sector. Some 50 European companies in the life sciences industry have received a total of €1.3 billion, backed by the European Fund for Strategic Investments, over the last four years.

Background information

About the European Investment Bank

The European Investment Bank is the long-term lending institution of the European Union owned by its Member States. It makes long-term finance available for sound investments in order to contribute towards EU policy goals. The EIB also supports investments outside the EU.

About BioNTech

Biopharmaceutical New Technologies (BioNTech) is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline.

About the Investment Plan for Europe

The Investment Plan for Europeis one of the EU’s key actions to boost investment in Europe, thereby creating jobs and fostering growth. To this end, smarter use is made of new and existing financial resources. The EIB Group is playing a vital role in this investment plan. With guarantees from the European Fund for Strategic Investments, the EIB and the European Investment Fund are able to take on a higher share of project risk, encouraging private investors to participate in the projects. To date, the projects and agreements approved under EFSI are expected to mobilise around €486 billion of investments and to benefit around 1.2 million small and medium-sized companies throughout the EU.

InnovFin – EU Finance for Innovators

Under Horizon 2020, the EU research and innovation programme for 2014-2020, the European Commission and the European Investment Bank Group (EIB and EIF) launched a new generation of financial instruments and advisory services in 2014 to help innovative firms access finance more easily. Until 2020, “InnovFin – EU Finance for Innovators” is offering a range of tailored products which provides financing in support of research and innovation by small, medium-sized and large companies and the promoters of research infrastructure.

the sting Milestones

Featured Stings

Can we feed everyone without unleashing disaster? Read on

These campaigners want to give a quarter of the UK back to nature

How to build a more resilient and inclusive global system

Stopping antimicrobial resistance would cost just USD 2 per person a year

Climate change is destroying a barrier that protects the US from hurricanes

Why the fight against nature loss should be a business priority

In an era of global uncertainty, the SDGs can be our guide

Fair completion rules and the law of gravity don’t apply to banks

State aid: Commission approves €380 million German rescue aid to Condor

Future fit: 3 ways fashion can be more sustainable

Data Protection Regulation one year on: 73% of Europeans have heard of at least one of their rights

The British are the most positive in Europe on the benefits of immigration

FROM THE FIELD: ‘A piece of me’ was taken

Ignorance or Refusal: Determinants in the individual’s choice for palliative care

EU Commission – US hasten talks to avoid NGO reactions on free trade agreement

France breaks budget promises once again and the EU’s finance offices are shaking

6 ways social innovators are responding to the COVID-19 pandemic

Hope for ‘long-elusive progress’ in negotiating peace in eastern Ukraine

Australia’s record heatwave: From fainting tennis players to dead fish

Yemen war: UN chief urges good faith as ‘milestone’ talks get underway in Sweden

WHO chief underscores need to address climate change following visit to Bahamas

The impact of COVID-19 on the life of the elderly

5 Ways Companies Can Progress More Women into Leadership Roles

This Latin American country is keeping COVID-19 firmly under control. How?

Shaping Europe’s digital future: op-ed by Ursula von der Leyen, President of the European Commission

Reducing disaster risk is a good investment, and ‘the right thing to do’, says Guterres

Burning Amazon rainforests: Darting towards the doom of Human Race

Young people meet in Malta to shape the future of Europe

The four top Americans who flew to Europe perplexed things about Trump’s intentions

3 actions for business to prepare for a post-pandemic future

Germany and OSCE support an east-west dialogue in Ukraine without exclusions

The global liberal order is in trouble – can it be salvaged, or will it be replaced?

Humanitarian Aid 2016: The needs, the highlights, the crisis and the relief

Thursday’s Daily Brief: Safeguarding civilians, strengthening Ebola response in DR Congo, marking Fistula Day, updates on CAR and Syria

Burundi election countdown amid ‘deteriorating’ human rights situation

This Syrian national has been trapped at Kuala Lumpur airport for 3 months

UN chief urges Hamas and Israel to ‘step back from the brink of another devastating conflict’ in Gaza

EU’s new environmental policy on biofuels impacts both the environment and the European citizen

These 3 countries are global offshore wind powerhouses

We need to talk about mental health at work, say employees

COVID-19, higher education and the impact on society: what we know so far and what could happen

Investing in education and skills can improve the health of both humans and planet. Here’s why

We need better alignment between climate and trade. Here’s a roadmap

The unpleasant truth of plastic straws

Asia and Pacific on course to miss all Sustainable Development Goals, says UN region chief

How global tech companies can champion ethical AI

European Union launches WTO trade dispute against Colombia’s unfair duties on frozen fries

EU Cohesion policy: Commission and EBRD promote innovative use of data in public procurement involving EU funds

FROM THE FIELD: What do you want to be when you grow up? One day I will…

Why the downturn is good news for subscription companies

Aid convoy for north-east Syria postponed over security concerns – UN relief chief

China’s stock markets show recovery signs while EU is closely watching in anticipation of the €10bn investment

Governments should step up their efforts to give people skills to seize opportunities in a digital world

Digital Single Market: Europe announces eight sites to host world-class supercomputers

Technological innovation can bolster trust and security at international borders. Here’s how

Challenges remain in DPRK despite ‘slight’ improvements in health, wellbeing: UNICEF

Gender Hierarchy in Medicine: From University to Specialization

On youth unemployment: unemployment is even bleaker for youth with disabilities

Youth not prioritised in new Commission

Can ECB’s €60 billion a month save Eurozone?

‘Complacency’ a factor in stagnating global vaccination rates, warn UN health chiefs

The EU Commission is lying to the “Right2Water” campaign

‘You can and should do more’ to include people with disabilities, wheelchair-bound Syrian advocate tells Security Council in searing speech

Guterres lauds UN peacekeeping, highlights need to bridge ‘critical’ gaps

More Stings?

Speak your Mind Here

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s